Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Days Sales Outstanding is 57.69 as of Dec. 2025, which is 2% below its 10-year median of 58.73. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 949 Drug Manufacturers companies, Labiana Health ranks better than 72.6% on this metric.
Labiana Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was €11.37 Mil. Labiana Health's Revenue for the
six
months ended in Dec. 2025 was €35.98 Mil.
Hence, Labiana Health's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 57.69.
The historical rank and industry rank for Labiana Health's Days Sales Outstanding or its related term are showing as below:
XMAD:LAB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.08 Med: 58.73 Max: 66.07
Current: 52.05
During the past 6 years, Labiana Health's highest Days Sales Outstanding was 66.07. The lowest was 48.08. And the median was 58.73.
XMAD:LAB's Days Sales Outstanding is ranked better than 72.6% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs XMAD:LAB: 52.05
Labiana Health's Days Sales Outstanding
declined
from Dec. 2024 (59.40) to Dec. 2025 (57.69).
Labiana Health (XMAD:LAB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Labiana Health Days Sales Outstanding Related Terms
Labiana Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Labiana Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Labiana Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Days Sales Outstanding of 57.69 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Labiana Health and its competitors. This is near median its historical median of 58.73. Over the past decade, Labiana Health's Days Sales Outstanding has ranged from 48.08 to 66.07. According to the industry distribution chart, Labiana Health ranks #260 out of 949 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Labiana Health's Days Sales Outstanding too high?
Labiana Health's current Days Sales Outstanding of 57.69 is near median its 10-year median of 58.73. Over the past 10 years, this metric has ranged from a low of 48.08 to a high of 66.07. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. Labiana Health's value of 57.69 is 19.9% below this industry median. Based on the distribution chart, Labiana Health ranks #260 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #260 out of 949 companies for Days Sales Outstanding. This puts Labiana Health in the upper half of its industry. The industry median Days Sales Outstanding is 72.00. Labiana Health's value of 57.69 is 19.9% below this benchmark. Historically, Labiana Health's own Days Sales Outstanding has ranged from 48.08 to 66.07 over the past decade. While the company's 10-year median is 58.73 vs. the industry median of 72.00, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Days Sales Outstanding of 57.69 is 19.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Days Sales Outstanding is 57.69, which is near median its own 10-year median of 58.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Days Sales Outstanding is 57.69, which is near median its 10-year median of 58.73 and 19.9% below the Drug Manufacturers industry median of 72.00. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Days Sales Outstanding is 57.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Days Sales Outstanding: 57.69 (near median its 10-year median of 58.73)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 19.9% below the Drug Manufacturers median (#260 of 949)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
